Literature DB >> 11641264

A molecular mechanism for genetic warfarin resistance in the rat.

R Wallin1, S M Hutson, D Cain, A Sweatt, D C Sane.   

Abstract

Warfarin targets vitamin K 2,3-epoxide reductase (VKOR), the enzyme that produces reduced vitamin K, a required cofactor for g-carboxylation of vitamin K-dependent proteins. To identify VKOR, we used 4'-azido-warfarin-3H-alcohol as an affinity label. When added to a partially purified preparation of VKOR, two proteins were identified by mass spectrometry as calumenin and cytochrome B5. Rat calumenin was cloned and sequenced and the recombinant protein was produced. When added to an in vitro test system, the 47 kDa recombinant protein was found to inhibit VKOR activity and to protect the enzyme from warfarin inhibition. Calumenin was also shown to inhibit the overall activity of the complete vitamin K-dependent g-carboxylation system. The results were repeated in COS-1 cells overexpressing recombinant calumenin. By comparing calumenin mRNA levels in various tissues from normal rats and warfarin-resistant rats, only the livers from resistant rats were different from normal rats by showing increased levels. Partially purified VKOR from resistant and normal rat livers showed no differences in Km-values, specific activity, and sensitivity to warfarin. A novel model for genetic warfarin resistance in the rat is proposed, whereby the concentration of calumenin in liver determines resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11641264     DOI: 10.1096/fj.01-0337fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

1.  siRNA silencing of calumenin enhances functional factor IX production.

Authors:  Nadeem Wajih; Susan M Hutson; Reidar Wallin
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

2.  Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?

Authors:  Ingrid Glurich; Richard L Berg; James K Burmester
Journal:  Clin Med Res       Date:  2013-05-08

Review 3.  Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2020-05-04       Impact factor: 5.568

4.  Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population.

Authors:  Rina Kimura; Yoshihiro Kokubo; Kotaro Miyashita; Ryoichi Otsubo; Kazuyuki Nagatsuka; Toshiho Otsuki; Toshiyuki Sakata; Junko Nagura; Akira Okayama; Kazuo Minematsu; Hiroaki Naritomi; Shigenori Honda; Kiyoshi Sato; Hitonobu Tomoike; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

5.  A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Authors:  D Voora; D C Koboldt; C R King; P A Lenzini; C S Eby; R Porche-Sorbet; E Deych; M Crankshaw; P E Milligan; H L McLeod; S R Patel; L H Cavallari; P M Ridker; G R Grice; R D Miller; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

6.  A hetero-dimer model for concerted action of vitamin K carboxylase and vitamin K reductase in vitamin K cycle.

Authors:  Sangwook Wu; Shubin Liu; Charles H Davis; Darrel W Stafford; John D Kulman; Lee G Pedersen
Journal:  J Theor Biol       Date:  2011-03-29       Impact factor: 2.691

7.  Calumenin but not reticulocalbin forms a Ca2+-dependent complex with thrombospondin-1. A potential role in haemostasis and thrombosis.

Authors:  Gry Aune Westergaard Hansen; Henrik Vorum; Christian Jacobsen; Bent Honoré
Journal:  Mol Cell Biochem       Date:  2008-08-08       Impact factor: 3.396

8.  Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.

Authors:  Marwa Ajmi; Asma Omezzine; Slim Achour; Dorra Amor; Haithem Hamdouni; Fatma Ben Fredj Ismaïl; Nabila Ben Rejeb; Chedia Laouani Kechrid; Essia Boughzela; Ali Bouslama
Journal:  Eur J Clin Pharmacol       Date:  2018-02-26       Impact factor: 2.953

9.  Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?

Authors:  Liliya Alexandrovna Belozerceva; Elena Nikolaevna Voronina; Natalia Viktorovna Kokh; Galina Alexandrovna Tsvetovskay; Andrei Pavlovich Momot; Galina Israilevna Lifshits; Maxim Leonidovich Filipenko; Andrei Ivanovich Shevela; Valentin Viktorovich Vlasov
Journal:  EPMA J       Date:  2012-09-27       Impact factor: 6.543

10.  Vitamin K epoxide reductase complex subunit 1 (Vkorc1) haplotype diversity in mouse priority strains.

Authors:  Ying Song; Nicole Vera; Michael H Kohn
Journal:  BMC Res Notes       Date:  2008-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.